FDA Grants Fast Track Designation to Leads Biolabs' Opamtistomig for Biliary Tract Cancer

Key Facts

1The US FDA granted Fast Track Designation to Opamtistomig for the treatment of advanced or metastatic biliary tract cancer.

The US Food and Drug Administration granted Fast Track Designation to Opamtistomig for the treatment of advanced or metastatic biliary tract cancer. GlobeNewswire reported that Nanjing Leads Biolabs announced its bispecific antibody received the designation for the first-line treatment of the condition.

The designation is intended to expedite the development and review of drugs that treat serious conditions and fill unmet medical needs. This regulatory milestone represents a positive development for the biotech firm's oncology pipeline.